1,295 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Novartis' Acute Heart Failure Drug Fails in Late-Stage Study http://www.zacks.com/stock/news/253764/novartis-acute-heart-failure-drug-fails-in-late-stage-study?cid=CS-ZC-FT-253764 Mar 22, 2017 - Novartis AG (NVS) recently suffered a setback on the announcement of disappointing data from a phase III study, RELAX-AHF-2, on pipeline candidate serelaxin (RLX030).
Uniqure NV (QURE) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow http://seekingalpha.com/article/4057235-uniqure-nv-qure-presents-oppenheimer-27th-annual-healthcare-conference-slideshow?source=feed_sector_healthcare Mar 22, 2017 - The following slide deck was published by uniQure N.V. in conjunction with this event.
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down http://www.zacks.com/stock/news/253718/array-biopharmas-nda-for-cancer-drug-withdrawn-shares-down?cid=CS-ZC-FT-253718 Mar 22, 2017 - Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.
Does Novartis (NVS) Stock Make a Good Value Pick? http://www.zacks.com/stock/news/253533/does-novartis-nvs-stock-make-a-good-value-pick?cid=CS-ZC-FT-253533 Mar 21, 2017 - Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017 http://www.zacks.com/stock/news/253511/6-reasons-to-invest-in-glaxosmithkline-gsk-stock-in-2017?cid=CS-ZC-FT-253511 Mar 21, 2017 - Glaxo carries a Zacks Rank #2 (Buy).
Lilly's Breast Cancer Combo Drug Phase III Results Positive http://www.zacks.com/stock/news/253465/lillys-breast-cancer-combo-drug-phase-iii-results-positive?cid=CS-ZC-FT-253465 Mar 21, 2017 - Eli Lilly and Company (LLY) recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer, met the primary endpoint of progression-free survival (PFS).
Novartis (NVS) Announces Positive Data on Heart Failure Drug http://www.zacks.com/stock/news/253425/novartis-nvs-announces-positive-data-on-heart-failure-drug?cid=CS-ZC-FT-253425 Mar 20, 2017 - Novartis AG (NVS) recently announced results of a new post-hoc analysis from the PARADIGM-HF study on heart failure drug Entresto.
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... http://www.gurufocus.com/news/493765/perceptive-advisors-llc-buys-neurocrine-biosciences-aclaris-therapeutics-galapagos-nv-sells-dexcom-aerie-pharmaceuticals-depomed Mar 20, 2017 - Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells DexCom, Aerie Pharmaceuticals, Depomed, Stocks: NBIX,ACRS,FOLD,ANIP,AVXS,GBT,GLPG,AVDL,ACOR,IRTC,C, release date:Mar 20, 2017
Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4 http://www.zacks.com/stock/news/253074/conatus-pharma-cnat-incurs-wider-than-expected-loss-in-q4?cid=CS-ZC-FT-253074 Mar 16, 2017 - Conatus Pharmaceuticals Inc. (CNAT) reported fourth-quarter 2016 loss of 35 cents per share, wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year-ago figure of 30 cents.
Glaxo Files for Label Expansion of Influenza Vaccine in US http://www.zacks.com/stock/news/252981/glaxo-files-for-label-expansion-of-influenza-vaccine-in-us?cid=CS-ZC-FT-252981 Mar 16, 2017 - GlaxoSmithKline plc (GSK) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA seeking approval to expand the label of Fluarix Quadrivalent ??? an influenza vaccine - for infants six months or older.
<<<Page 120>